Evogliptin
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Diabetes & Endocrine treatment.
🧴 Clinical Application
Take orally with or immediately after meals (breakfast and dinner) with a full glass of water. Starting with a low dose (500 mg once or twice daily) and titrating slowly over weeks substantially reduces gastrointestinal side effects. Swallow sustained-release/prolonged-release tablets whole; do not break, chew, or crush.
⚠️ Side Effects
Common: Diarrhea, nausea, vomiting, abdominal bloating, flatulence, anorexia, metallic taste, vitamin B12 deficiency with prolonged use. Rare/Severe: Boxed warning: Lactic acidosis (rare but life-threatening accumulation with 50% mortality); acute kidney injury, and severe megaloblastic anemia.
🛡️ Safety Warnings
Black box warning: Lactic acidosis; risk is heightened in renal impairment, sepsis, acute congestive heart failure, and heavy alcohol intake. Contraindicated if eGFR < 30 mL/min; dose should not exceed 1000 mg/day if eGFR is 30-44 mL/min. Must be withheld temporarily at the time of or prior to iodinated radiocontrast imaging procedures and for 48 hours post-procedure until renal function is re-evaluated. Periodic serum vitamin B12 monitoring is advised.
Jan Aushadhi Products containing Evogliptin
Found 3 generic formulation(s) containing this active ingredient.
Evogliptin 5mg + Metformin Hydrochloride Sustained Release 1000mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).
Evogliptin 5mg + Metformin Hydrochloride Sustained Release 500mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).
Evogliptin Tartarate 5mg Tablets
Evogliptin Tartarate 5mg Tablets is an evidence-based antidiabetic and endocrine pharmaceutical formulation. It acts by regulating metabolic homeostasis, optimizing hormonal signaling pathways, and normalizing blood glucose levels.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Evogliptin.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Evogliptin 5mg + Metformin Hydrochloride Sustained Release 1000mg Tablets | 10's | Under Process | N/A | N/A | N/A |
| Evogliptin 5mg + Metformin Hydrochloride Sustained Release 500mg Tablets | 10's | Under Process | N/A | N/A | N/A |
| Evogliptin Tartarate 5mg Tablets | 10's | Under Process | N/A | N/A | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Evogliptin generics.